{"id":"NCT01791972","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","briefTitle":"Efficacy of Albuterol SPIROMAX® in Adult and Adolescent Patients With Exercise-Induced Bronchoconstriction (EIB)","officialTitle":"A Single-Dose Study to Assess the Efficacy of Albuterol SPIROMAX® in Adult and Adolescent Patients With Exercise-Induced Bronchoconstriction (EIB)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-03","primaryCompletion":"2013-05","completion":"2013-06","firstPosted":"2013-02-15","resultsPosted":"2015-05-19","lastUpdate":"2015-06-18"},"enrollment":38,"design":{"allocation":"RANDOMIZED","model":"CROSSOVER","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Exercise-Induced Bronchoconstriction (EIB)"],"interventions":[{"type":"DRUG","name":"Albuterol Spiromax","otherNames":["Albuterol DPI, ProAir® RespiClick"]},{"type":"DRUG","name":"Placebo Spiromax","otherNames":[]}],"arms":[{"label":"Albuterol Spiromax / Placebo Spiromax","type":"EXPERIMENTAL"},{"label":"Placebo Spiromax / Albuterol Spiromax","type":"EXPERIMENTAL"}],"summary":"The primary objective of this study is to evaluate the efficacy of a single dose (2 inhalations, 180 mcg total) of Albuterol SPIROMAX (90 mcg per inhalation) versus placebo in patients with EIB.","primaryOutcome":{"measure":"Maximum Percentage Fall From Baseline in Forced Expiratory Volume in 1 Second (FEV1) up to 60 Minutes After the Exercise Challenge","timeFrame":"Days 1 and 7; up to 60 minutes post-exercise challenge","effectByArm":[{"arm":"Albuterol Spiromax 180 mcg","deltaMin":6.21,"sd":1.443},{"arm":"Placebo Spiromax","deltaMin":22.38,"sd":1.444}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":7},"locations":{"siteCount":6,"countries":["United States"]},"refs":{"pmids":["26475054"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":38},"commonTop":[]}}